Hepatitis C

VA offers hepatitis, HIV screening to veterans who received improper dental care

VA offers hepatitis, HIV screening to veterans who received improper dental care

By

A VA center in Wisconsin is advising veterans to be screened for hepatitis and HIV after receiving care from a dentist who did not follow VA procedures.

Ledipasvir-sofosbuvir treatment safe for kidney recipients with hepatitis C

Ledipasvir-sofosbuvir treatment safe for kidney recipients with hepatitis C

Treatment for 12 or 24 weeks is safe and efficacious for kidney transplant recipients with hepatitis C virus.

Probable interaction identified between hepatitis C treatments

Probable interaction identified between hepatitis C treatments

Researchers identified an interaction between ribavirin with paritaprevir/ritonavir/ombitasvir and dasabuvir.

More than 1 million people treated with new hepatitis C drugs

More than 1 million people treated with new hepatitis C drugs

By

The cost of the new hepatitis C drugs in low- and certain middle-income countries is rapidly declining, according to a WHO study.

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

By

The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.

Reducing the duration of hepatitis C therapy may be effective

Reducing the duration of hepatitis C therapy may be effective

By

Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.

Patients with hepatitis C prefer therapy with sofosbuvir and ribavirin

Patients with hepatitis C prefer therapy with sofosbuvir and ribavirin

In patients with Hepatitis C, Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy.

Hepatitis C virus core antigen testing is a highly accurate diagnostic tool

Hepatitis C virus core antigen testing is a highly accurate diagnostic tool

By

HCVcAg assays with signal amplification have the potential to replace NAT in settings with high HCV prevalence.

New hepatology rotation increases knowledge of liver disease among residents

New hepatology rotation increases knowledge of liver disease among residents

A new hepatology rotation increased the mean comfort level for managing several liver diseases.

Shared drug paraphernalia linked to hep C transmission

Shared drug paraphernalia linked to hep C transmission

In a study, 24% of confiscated drug snorting straws tested positive for human blood.

Direct-acting antivirals in hepatitis C do not reduce hepatocellular carcinoma occurrence

Direct-acting antivirals in hepatitis C do not reduce hepatocellular carcinoma occurrence

By

Patients previously treated for HCC have a high risk of tumor recurrence in the long term.

Epclusa approved to treat chronic hepatitis C

Epclusa approved to treat chronic hepatitis C

The combination drug treats 6 strains of chronic hepatitis C.

Multidisciplinary approach improves outcomes in hepatitis C

Multidisciplinary approach improves outcomes in hepatitis C

By

Patients with hepatitis C who had a multidisciplinary team during treatment had improved outcomes.

Hepatitis C mortality increasing, now leading cause of death among all infectious diseases

Hepatitis C mortality increasing, now leading cause of death among all infectious diseases

By

The number of deaths associated with hepatitis C is higher than the total number of deaths resulting from 60 other infectious diseases.

Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma

Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma

By

Direct-acting antivirals pose challenges in patients with hepatitis C and prior hepatocellular carcinoma

HCV, HIV co-infection linked to increased diabetes risk

HCV, HIV co-infection linked to increased diabetes risk

Treatment guidelines must expand to focus on patients co-infected with both HCV and HIV.

Sustained virological response found at 5 years in low-risk patients with HCV

Sustained virological response found at 5 years in low-risk patients with HCV

Patients with HCV/HIV coinfections had a much higher risk of HCV recurrence.

Signs and symptoms of hepatitis C virus infection

Signs and symptoms of hepatitis C virus infection

Education of high risk populations and regular testing are crucial steps clinicians can take to stem the spread of hepatitis C infection.

CDC works to eliminate HCV transmission in hemodialysis

CDC works to eliminate HCV transmission in hemodialysis

The organization encourages dialysis providers to improve current infection control practices.

FDA approves Zepatier for hepatitis C genotypes 1 and 4

FDA approves Zepatier for hepatitis C genotypes 1 and 4

By

Zepatier has been approved by the FDA to treat hepatitis C virus genotypes 1 and 4 infections in adult patients.

Few nurses compliant with bloodborne pathogen precautions

Few nurses compliant with bloodborne pathogen precautions

Fewer than 20% of surveyed nurses report total adherence to the standard precautions meant to prevent bloodborne pathogen transmission.

Clinicians encouraged to screen for hepatitis C based on birth year

Clinicians encouraged to screen for hepatitis C based on birth year

Only 8.3% of eligible patients at 14 health centers were screened for hepatitis C based on guidelines presented in 2013.

FDA issues warning for two hepatitis C drugs

FDA issues warning for two hepatitis C drugs

Hepatitis C drugs Viekira Pak and Technivie have been recently linked to serious liver damage in patients with advanced liver disease, said the FDA.

Statins slow progression of liver disease in patients with HIV, Hep C

Statins slow progression of liver disease in patients with HIV, Hep C

Statin use in co-infected patients showed a slowed progression of liver disease, according to a study conducted at the Johns Hopkins Moore Clinic for HIV Care.

Treatment for HCV genotype 1 infection

Treatment for HCV genotype 1 infection

Viekira Pak is indicated for chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin.

Technivie approved for chronic hepatitis C

Technivie approved for chronic hepatitis C

The FDA approved Technivie (ombitasvir, paritaprevir, ritonavir) for chronic hepatitis C gentotype 4 infection.

Two combination treatments show promise for HIV, HCV coinfection

Two combination treatments show promise for HIV, HCV coinfection

The combinations of ledipasvir plus sofosbuvir and daclatasvir plus sofosbuvir may effectively treat HIV, HCV coinfection.

Hepatitis C cases underreported to CDC

Hepatitis C cases underreported to CDC

Very few cases of hepatitis C meet the CDC's criteria for reporting.

Sign Up for Free e-newsletters